Tegoprazan-Amoxicillin Dual Therapy for Clarithromycin-Resistant <i>Helicobacter pylori</i>: A Feasibility Pilot Study.

ABSTRACT: Tegoprazan (TPZ) has the potential to enhance Helicobacter pylori eradication. This study aimed to investigate the efficacy of TPZ-amoxicillin (TA) dual therapy against clarithromycin-resistant H. pylori strains. All H. pylori-positive patients were diagnosed by real-time polymerase chain reaction that can detect point mutations causing clarithromycin resistance. Patients infected with clarithromycin-resistant H. pylori received TA dual therapy consisting of 50 mg TPZ twice daily and high-dose amoxicillin (3 g per day) for 2 weeks. A total of 57 patients received TA dual therapy. There was a significant difference in H. pylori eradication rates between the treatment-naïve (n = 40) and treatment-experienced (n = 17) groups in the intention-to

SUBMITTER: Cho JH 

PROVIDER: S-EPMC12566439 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature